News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • TSMC set for fifth straight record quarter as AI-driven demand lifts 3nm/2nm and advanced packaging, prompting expected revenue and capex upgrades.
  • SK Hynix shares slide after U.S. ADR debut amid broker downgrades over weak memory prices and DRAM bit growth.
  • Erasca priced upsized public offering of 31.4 million shares at $17.50, targeting roughly $550 million to fund R&D and corporate needs.
  • HHS rescinded enforcement of a freeze that targeted about $10 billion for five Democratic-led states, ending that funding restriction after court challenges.
  • Equity markets: chipmakers show divergence as AI winners like TSMC gain while memory players face pressure.

Latest Articles

Woodside Says It Is Not in Talks With Exxon Over Possible Takeover

Woodside Says It Is Not in Talks With Exxon Over Possible Takeover

Woodside Energy Ltd said on Monday it was not engaged in any discussions about a takeover by Exxon Mobil, responding to media reports last week that the U.S. oil major was considering an offer. The comments come as liquefied natural gas (LNG) remains a focal point for growth amid rising global power demand linked to AI data centers, and after regio…

Markets React to U.S.-Iran Agreement on Strait of Hormuz Access

Markets React to U.S.-Iran Agreement on Strait of Hormuz Access

Asian equity and bond markets advanced on Monday following a diplomatic agreement between the United States and Iran aimed at reopening the strategic Strait of Hormuz and lifting U.S. restrictions on Iran. The resolution triggered a broad sell-off in the U.S. dollar, supported equity futures, and prompted a decline in crude oil prices, though marke…

UK Banks Report Sharp Rise in APP Fraud Losses After Refund Rule Change

UK Banks Report Sharp Rise in APP Fraud Losses After Refund Rule Change

Losses tied to authorised push payment (APP) fraud climbed sharply in the latest industry figures, with banks reporting a 19% increase to £576.4 million last year. The rise comes amid a new reimbursement rule, introduced in October 2024, that obliges banks and payments firms to refund victims up to £85,000 and has intensified debate over the role o…

Asian Stocks Rally as Gulf Deal Eases Energy Concerns; Oil and Dollar Slip

Asian Stocks Rally as Gulf Deal Eases Energy Concerns; Oil and Dollar Slip

Asian equities jumped on Monday after reports that the United States and Iran had reached a deal affecting the Strait of Hormuz. The news weakened oil prices and the U.S. dollar, bolstering risk appetite across equities and futures while sending Treasury futures higher. Policymakers face a lighter near-term inflation risk just before multiple centr…

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026

Zymeworks Inc. announced new Phase 1 clinical trial data for their antibody-drug conjugate ZW191 targeting folate receptor alpha in patients with platinum-resistant ovarian cancer and endometrial cancer. The data demonstrate high confirmed objective response rates (78.6% in FRα-positive ovarian cancer and 47.4% in FRα-negative cases) and durable re…

Moscow Close: MOEX Flat as Broader Russian Market Moves Lower

Moscow Close: MOEX Flat as Broader Russian Market Moves Lower

Russian equities finished the session lower on Sunday, while the MOEX Russia Index closed unchanged, marking a new six-month low. Utilities names led gains, with ROSSETI, Aeroflot and Unipro among the top performers. Several large-cap stocks including PIK, Rusal and TATNEFT registered declines. Market breadth favored advancers, volatility readouts …

Agentic Shopping: How Far Can AI Go in Buying for Consumers?

Agentic Shopping: How Far Can AI Go in Buying for Consumers?

Summary: A Bernstein analysis tested five agentic shopping tools to assess whether AI agents can fully carry out shopping tasks end to end. The study compared general-purpose large language models with retail-native assistants, finding foundational models excel at discovery across a fragmented web but lack access to structured catalogue, pricing, i…

Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026

Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026

Crinetics Pharmaceuticals presented positive Phase 2 clinical data showing their investigational oral drug Atumelnant significantly reduced androgen levels while enabling glucocorticoid dose reductions in adults with classic congenital adrenal hyperplasia (CAH). Additionally, initial Phase 1b/2a trial results in ACTH-dependent Cushing’s syndrome de…

Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control

Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control

Crinetics Pharmaceuticals presented up to two years of data from PATHFNDR-1 and PATHFNDR-2 open-label extension studies showing that PALSONIFY (paltusotine), an oral somatostatin receptor agonist, maintains stable IGF-1 levels, controls acromegaly symptoms, and stabilizes or reduces pituitary tumor volume. The data confirmed durable disease control…

Positioning for a Strategic Pivot at Headwater Exploration

Positioning for a Strategic Pivot at Headwater Exploration

Headwater Exploration (CDDRF) is trading around short-term moving averages as short interest unwinds. Management hinted at higher capex and faster growth in prior guidance; an earnings-driven strategy update could spark a directional move. We present a mid-term long trade with entry at $9.26, a $12.00 target and an $8.00 stop — sized for a medium-r…

SpaceX's Launch Cost Breakthrough Rewrites Its Market Prospects

SpaceX's Launch Cost Breakthrough Rewrites Its Market Prospects

Wolfe Research has initiated coverage on SpaceX (SPCX) with a $175 price target after the company's IPO, arguing that reusability-driven reductions in internal launch costs and a Starlink connectivity inflection point create a durable competitive advantage and substantial earnings upside by 2030. The firm projects steep revenue growth and margin ex…

Carney Returns to Ancestors' Village in Ireland Ahead of G7 Visit

Carney Returns to Ancestors' Village in Ireland Ahead of G7 Visit

Canadian Prime Minister Mark Carney traveled to Aughagower in western Ireland to trace his family roots, meet distant relatives and participate in local religious and commemorative rituals. On a trip en route to the G7 meeting in France, he used public appearances in Dublin to urge deeper cooperation between Canada, Ireland and Europe as the post-C…

Anger at G7 Sparks Damage in Geneva as Protesters Burn Tesla and Smash Bank Windows

Anger at G7 Sparks Damage in Geneva as Protesters Burn Tesla and Smash Bank Windows

Thousands marched in Geneva to protest the Group of Seven summit scheduled across the border, expressing opposition to concentrated political and economic power. While the demonstration was mostly peaceful, some participants set fire to a Tesla and damaged a bank, prompting a heavy police presence and preemptive security measures by local businesse…

Deadly Strikes in Gaza Kill Six as Mediators Push to Revive Truce Plan

Deadly Strikes in Gaza Kill Six as Mediators Push to Revive Truce Plan

At least six Palestinians were killed in Gaza in separate incidents of strikes and gunfire, health officials said, as mediators concluded week-long discussions aimed at implementing the second phase of a U.S.-brokered ceasefire plan. The violence coincided with diplomatic efforts to secure disarmament and an Israeli withdrawal outlined in a 15-poin…

BofA: Further 3% S&P 500 Slide Could Prompt Additional Systematic Selling

BofA: Further 3% S&P 500 Slide Could Prompt Additional Systematic Selling

Bank of America analysts say Commodity Trading Advisors (CTAs) have pared equity longs after recent market weakness but retain net long exposure. Their models suggest that a further roughly 3% fall in the S&P 500 - and a roughly 5% fall in the NASDAQ-100 - could trigger another wave of systematic selling, particularly as stop-loss frameworks bite. …

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting

Celldex Therapeutics presented long-term Phase 2 data demonstrating that barzolvolimab treatment yields rapid, significant, and durable improvements in angioedema symptoms among patients with moderate to severe chronic spontaneous urticaria (CSU). Up to 64% of patients remained angioedema-free seven months post-treatment, indicating potential disea…

Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)

Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)

Mineralys Therapeutics presented post hoc proteomic analysis data indicating that lorundrostat, an investigational aldosterone synthase inhibitor, significantly reduces biomarkers linked to heart failure risk in patients with uncontrolled hypertension. These findings support lorundrostat's therapeutic potential and coincide with ongoing FDA review.…

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026

Upstream Bio presented new responder analyses from its Phase 2 VIBRANT trial demonstrating that Verekitug, a TSLP receptor antagonist administered every three months, achieved clinically meaningful improvements in nasal polyp score and multiple key symptoms in a significant majority of patients with chronic rhinosinusitis with nasal polyps (CRSwNP)…